Hemispherx BioPharma, Inc (HEB) Short Interest Down 22.2% in September
Hemispherx BioPharma, Inc (NYSE:HEB) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 223,168 shares, a decrease of 22.2% from the September 15th total of 286,805 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 83,996 shares, the days-to-cover ratio is presently 2.7 days.
Shares of Hemispherx BioPharma (NYSE:HEB) opened at 1.16 on Wednesday. The stock has a 50 day moving average of $1.43 and a 200-day moving average of $1.53. Hemispherx BioPharma has a 52-week low of $0.72 and a 52-week high of $2.64. The stock’s market capitalization is $24.06 million.
Hemispherx BioPharma (NYSE:HEB) last released its earnings results on Monday, August 15th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the firm posted ($0.02) earnings per share.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Stock Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related stocks with our FREE daily email newsletter.